Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14710772 | 0.93 | LPAR1 (0.51) | LPAR1LPAR3MGLL | |
| SCHEMBL14710283 | 0.83 | LPAR1 (0.65) | LPAR1LPAR3 | |
| SCHEMBL16210862 | 0.83 | LPAR1 (0.65) | LPAR1LPAR3 | |
| SCHEMBL12989804 | 0.82 | LPAR1 (0.61) | LPAR1LPAR3SMN1; SMN2ROCK2 | |
| SCHEMBL14711064 | 0.81 | SMN1; SMN2 (0.41) | LPAR1LPAR3MGLLSMN1; SMN2ROCK2 | |
| SCHEMBL14790495 | 0.80 | ROCK2 (0.39) | LPAR1LPAR3MGLLSMN1; SMN2ROCK2 | |
| SCHEMBL14711376 | 0.80 | NPC1 (0.39) | MGLLSMN1; SMN2ROCK2CSNK1D | |
| SCHEMBL14710311 | 0.79 | SMN1; SMN2 (0.43) | LPAR1LPAR3MGLLSMN1; SMN2ROCK2 | |
| SCHEMBL14710295 | 0.78 | LPAR1 (0.61) | LPAR1LPAR3MGLLSMN1; SMN2 | |
| SCHEMBL14712129 | 0.78 | LPAR1 (0.52) | LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | LPAR1 1/4885LPAR3 5/4885MGLL 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.